News

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra
Madrigal Pharmaceuticals has a first mover advantage in the huge MASH market due to the approval of Rezdiffra. Read whether I ...
The Manila Times17h
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy
Ingelheim, Germany, May 6, 2025 - Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential ...